As of June 13, 2025, Neuropathix Inc (NPTX) reports a ROE (Return on Equity) of 89.24%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Neuropathix Inc's ROE (Return on Equity)
Over recent years, Neuropathix Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | 89.24% |
| 2020-12-31 | 142.03% |
| 2019-12-31 | 203.30% |
| 2018-12-31 | 70.09% |
| 2017-12-31 | 45.96% |
This fluctuation highlights how Neuropathix Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Neuropathix Inc's ROE (Return on Equity) to Peers
To better understand Neuropathix Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Neuropathix Inc (NPTX) | 89.24% |
| Medican Enterprises Inc (MDCN) | 680.75% |
| Spotlight Innovation Inc (STLT) | 396.49% |
| Quanta Inc (QNTA) | 386.33% |
| Cannabis Global, Inc. (CBGL) | 354.30% |
| AtheroNova Inc (AHROQ) | 312.21% |
Compared to its competitors, Neuropathix Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.